On July 13, Quantinuum declined 5.34% in regular trading, trading at $66.11 per share with turnover of $19.50 million. The stock has been experiencing persistent wide-range volatility since multiple top-tier Wall Street investment banks collectively initiated coverage on June 29.

The sell-side coverage reveals a striking valuation gap, with target prices ranging from $78 (Morgan Stanley, Equal Weight) to $155 (Rosenblatt, Buy) — nearly a 2x spread reflecting fundamental disagreement over quantum computing commercialization prospects. Other targets include JPMorgan at $97 (Overweight), BofA at $100 (Buy), UBS at $93 (Buy), Mizuho at $90 (Outperform), and Jefferies at $90 (Buy).

Adding to the volatility, the company listed just over one month ago at $60 per share and reported Q1 revenue of $5.24 million, down 73% year-over-year, with net losses widening to $136.5 million. The combination of early-stage public market trading, severe fundamental pressure, and wide analyst disagreement continues to fuel sharp price swings.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)